



(51) International Patent Classification:

C12N 15/11 (2006.01) *C07H 21/04* (2006.01)
C12N 15/113 (2010.01) *C07H 19/167* (2006.01)
A61K 31/713 (2006.01) *C07H 21/02* (2006.01)

(21) International Application Number:

PCT/US2022/080448

(22) International Filing Date:

23 November 2022 (23.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/283,177 24 November 2021 (24.11.2021) US
 63/287,952 09 December 2021 (09.12.2021) US
 63/302,976 25 January 2022 (25.01.2022) US
 63/339,873 09 May 2022 (09.05.2022) US

(71) Applicant: **ADARX PHARMACEUTICALS, INC.**
 [US/US]; 5871 Oberlin Drive, Suite 200, San Diego, CA
 92121 (US).

(72) Inventors: **LI, Zhen**; c/o Adarx Pharmaceuticals, Inc.,
 5871 Oberlin Drive, Suite 200, San Diego, CA 92121
 (US). **ZHU, Rui**; c/o Adarx Pharmaceuticals, Inc., 5871
 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
ZHOU, Zhiqing (Joel); c/o Adarx Pharmaceuticals, Inc.,
 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
STUDER, Sean; c/o Adarx Pharmaceuticals, Inc., 5871
 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
FULTZ, Kimberly; c/o Adarx Pharmaceuticals, Inc., 5871
 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).
CORREIA, Jean, Da Silva; c/o Adarx Pharmaceuticals,
 Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121
 (US).

(74) Agent: **BOWLER, Joseph, M.** et al.; Wolf, Greenfield &
 Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206
 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
 KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
 LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
 RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
 ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, CV,
 GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
 SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
 claims and to be republished in the event of receipt of
 amendments (Rule 48.2(h))

(54) Title: COMPLEMENT FACTOR B-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB mRNA in a cell or animal. In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB protein in a cell or animal.